Hyderabad-based drugmaker will license and supply 75 generic drugsthat address a $200m market to Pfizer
After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen.
The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe.
That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.
The US Food and Drug Administration (USFDA) has given tentative approval to Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), to market Escitalopram Oxalate tablets in variable strengths.
After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen. The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe. That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.
Mumbai-based generic drug maker Piramal Healthcare Limited has completed its previously announced acquisition of Minrad International, a provider of generic inhalation anesthetics. 
